Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Stathis

Showing results (41-50 of 131) with videos related to

Pageof 14
Sort By:
Hematological Oncology|October 26, 2020
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomasBarbara Vannata, Anna Vanazzi, Mara Negri, et al.
Oncotarget|February 12, 2015
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseAfua Adjeiwaa Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Swiss Medical Weekly|September 28, 2023
Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre studyElona Cekani, Carolina Martorell, Francesco Martucci, et al.
Investigational New Drugs|February 15, 2023
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a studyMarkus Joerger, Thomas Hundsberger, Simon Haefliger, et al.
The AAPS Journal|December 11, 2021
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, William Townsend, Weiyun Ai, et al.
British Journal of Haematology|August 4, 2015
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical modelsElena Bernasconi, Eugenio Gaudio, Ivo Kwee, et al.
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Leukemia & Lymphoma|August 19, 2021
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomasMaria C Pirosa, Lu Zhang, Felicitas Hitz, et al.
Oncotarget|August 6, 2016
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphomaEugenio Gaudio, Chiara Tarantelli, Maurilio Ponzoni, et al.
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
Pageof 14

Showing results (41-50 of 131) with videos related to

Sort By:
Pageof 14
Hematological Oncology|October 26, 2020
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomasBarbara Vannata, Anna Vanazzi, Mara Negri, et al.
Oncotarget|February 12, 2015
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseAfua Adjeiwaa Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Swiss Medical Weekly|September 28, 2023
Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre studyElona Cekani, Carolina Martorell, Francesco Martucci, et al.
Investigational New Drugs|February 15, 2023
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a studyMarkus Joerger, Thomas Hundsberger, Simon Haefliger, et al.
The AAPS Journal|December 11, 2021
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, William Townsend, Weiyun Ai, et al.
British Journal of Haematology|August 4, 2015
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical modelsElena Bernasconi, Eugenio Gaudio, Ivo Kwee, et al.
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Leukemia & Lymphoma|August 19, 2021
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomasMaria C Pirosa, Lu Zhang, Felicitas Hitz, et al.
Oncotarget|August 6, 2016
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphomaEugenio Gaudio, Chiara Tarantelli, Maurilio Ponzoni, et al.
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
Pageof 14